Shifting GLP-1 research and development: Lessons learned from the first-generation 

Summary

Article discusses the evolving R&D landscape for GLP-1 receptor agonists and metabolic therapies, highlighting expansion beyond type 2 diabetes to include MASH, cardiovascular event reduction, and renal disease management. This is a general editorial overview without specific company, trial, or regulatory catalyst information.